Domain Therapeutics’ innovative business model gains validation through Prexton Therapeutics’ acquisition by Lundbeck for up to $1.1 billion
Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biote...
Continue Reading →
